Natera Inc (NTRA)

$165.71 +3.24 (1.99%)
Market Cap 22.30B
Revenue (ttm) 1.70B
Net Income (ttm) -190.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11.22%
Debt to Equity Ratio 0.06
Volume 1,012,100
Avg Vol 1,428,894
Day's Range N/A - N/A
Shares Out 137.25M
Stochastic %K 82%
Beta 1.76
Analysts Strong Sell
Price Target $204.45

Company Profile

Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples und...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 980 9190
Address:
13011 McCallen Pass, Building A Suite 100, Austin, United States
JudithJohnson203
JudithJohnson203 Aug. 25 at 6:22 PM
$NTRA Diagnostics leader, continuation if it holds the breakout base
0 · Reply
ZacksResearch
ZacksResearch Aug. 25 at 5:40 PM
$NTRA unveils AI platform — game-changer for precision oncology? 🚀 Natera's proprietary AI foundation integrates massive datasets to enhance drug development and clinical decision-making. Shares up 2.3% post-announcement, with a 4.6% YTD gain compared to industry's 0.9%. Discover the full impact here 👉 https://www.zacks.com/stock/news/2742434/natera-shares-rise-on-the-launch-of-ai-platform-for-precision-oncology?cid=sm-stocktwits-2-2742434-body-9397&ADID=SYND_STOCKTWITS_TWEET_2_2742434_BODY_9397
0 · Reply
ZacksResearch
ZacksResearch Aug. 25 at 4:40 PM
$NTRA popping on AI-fueled cancer care 🚀 Shares are climbing as the company rolls out its own AI platform, powered by massive oncology datasets to push precision oncology forward. See what’s driving the momentum here 👉 https://www.zacks.com/stock/news/2742434/natera-shares-rise-on-the-launch-of-ai-platform-for-precision-oncology?cid=sm-stocktwits-2-2742434-teaser-9396&ADID=SYND_STOCKTWITS_TWEET_2_2742434_TEASER_9396
0 · Reply
CaptainAmrica
CaptainAmrica Aug. 23 at 5:56 PM
$NTRA. Still working....and Holding.
0 · Reply
JasonCO
JasonCO Aug. 22 at 8:18 PM
$NTRA beast is back
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 22 at 10:20 AM
WATCHLIST AUG 22 2025 $NTRA Natera Launches Proprietary AI Foundation Models Built On 250,000+ Tumor Exomes And 1M+ Plasma Timepoints To Advance Oncology Diagnostics And Therapeutics $FFAI Faraday X Announces FX Super One Multi Purpose Vehicle Successfully Completes First Federal Motor Vehicle Safety Standards Development Tests $QTRX Quanterix Accelerator Laboratory Receives New York State Clinical Laboratory Permit; Permit Approval Enables Expanded Research Capabilities And Underscores Commitment To Accuracy, Reliability, And Scientific Excellence $ROST Ross Stores shares are trading higher after the company reported better-than-expected Q2 EPS results and issued Q4 GAAP EPS guidance above estimates. $AMBO Ambow Education Launches HybriU Events To Power Immersive, AI-Driven Interactive Live Experiences With Global Multi-Language Accessibility
0 · Reply
StockElementCorporation
StockElementCorporation Aug. 21 at 2:38 PM
$NTRA - Up +2.6% today
0 · Reply
StockElementCorporation
StockElementCorporation Aug. 20 at 6:59 PM
$NTRA - Bullish call flow
0 · Reply
vwapsmash_
vwapsmash_ Aug. 18 at 4:21 PM
$NTRA Natera's genetic testing gains traction though reimbursement challenges remain.
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 18 at 10:56 AM
$NTRA loaded
0 · Reply
Latest News on NTRA
Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer

Aug 25, 2025, 8:00 AM EDT - 1 day ago

Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer

Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine

Aug 22, 2025, 6:04 AM EDT - 4 days ago

Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation

Aug 22, 2025, 5:00 AM EDT - 5 days ago

Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

Aug 18, 2025, 6:00 AM EDT - 8 days ago

IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

Natera shares surge 17% after strong Q2 results and upgraded guidance

Aug 8, 2025, 4:08 PM EDT - 18 days ago

Natera shares surge 17% after strong Q2 results and upgraded guidance

Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 10:43 PM EDT - 19 days ago

Natera, Inc. (NTRA) Q2 2025 Earnings Call Transcript

Natera Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 19 days ago

Natera Reports Second Quarter 2025 Financial Results

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

Aug 7, 2025, 7:00 AM EDT - 19 days ago

Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions

Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations

Aug 1, 2025, 7:00 AM EDT - 25 days ago

Natera Highlights Latest Prospera™ Data at WTC 2025; 16 Abstracts Including Five Oral Presentations

Natera to Report Its Second Quarter Results on August 7, 2025

Jul 31, 2025, 7:00 AM EDT - 26 days ago

Natera to Report Its Second Quarter Results on August 7, 2025

Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer

Jul 29, 2025, 7:00 AM EDT - 4 weeks ago

Natera Announces Launch of ABCSG 61 (“TEODOR”), a Randomized Controlled Trial of Signatera™ in Early-Stage Breast Cancer

PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT

Jul 24, 2025, 8:00 AM EDT - 4 weeks ago

PEDAL Study Successful, Shows Monitoring with Prospera™ Kidney Provides Accurate Prognosis of Long-Term Clinical Outcomes Following Rejection; Now Published in AJT

Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer

Jul 7, 2025, 7:00 AM EDT - 7 weeks ago

Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer

Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD

Jul 1, 2025, 4:05 PM EDT - 2 months ago

Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD

Natera Announces Medicare Coverage for Signatera™ Genome

Jun 4, 2025, 7:00 AM EDT - 2 months ago

Natera Announces Medicare Coverage for Signatera™ Genome

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

Jun 2, 2025, 4:05 PM EDT - 3 months ago

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

May 22, 2025, 5:08 PM EDT - 3 months ago

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

Natera: The Clues In Q1 Earnings

May 16, 2025, 8:41 AM EDT - 3 months ago

Natera: The Clues In Q1 Earnings

Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:58 PM EDT - 3 months ago

Natera, Inc. (NTRA) Q1 2025 Earnings Call Transcript

Natera Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 3 months ago

Natera Reports First Quarter 2025 Financial Results

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

May 8, 2025, 10:30 AM EDT - 3 months ago

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

May 7, 2025, 7:00 AM EDT - 3 months ago

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera

May 5, 2025, 7:00 AM EDT - 4 months ago

Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera

Natera to Report its First Quarter Results on May 8, 2025

May 1, 2025, 7:00 AM EDT - 4 months ago

Natera to Report its First Quarter Results on May 8, 2025

Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction

Apr 29, 2025, 4:05 PM EDT - 4 months ago

Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

Apr 29, 2025, 11:45 AM EDT - 4 months ago

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

ACLX ISRG MASI MCK PEN TMO UNH

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

Apr 24, 2025, 7:00 AM EDT - 4 months ago

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

Apr 22, 2025, 4:05 PM EDT - 4 months ago

Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

Mar 25, 2025, 7:00 AM EDT - 5 months ago

DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time

Mar 17, 2025, 11:52 AM EDT - 5 months ago

Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time

Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer

Mar 10, 2025, 8:00 AM EDT - 6 months ago

Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer

Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD

Mar 4, 2025, 7:00 AM EST - 6 months ago

Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD

Natera, Inc. (NTRA) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 12:23 AM EST - 6 months ago

Natera, Inc. (NTRA) Q4 2024 Earnings Call Transcript

Natera Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 4:05 PM EST - 6 months ago

Natera Reports Fourth Quarter and Full Year 2024 Financial Results

Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer

Feb 25, 2025, 6:00 AM EST - 6 months ago

Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer

Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025

Feb 18, 2025, 9:00 AM EST - 6 months ago

Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025

NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma

Feb 10, 2025, 7:00 AM EST - 7 months ago

NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma

Natera Announces National Commercial Coverage for its Fetal RhD NIPT

Feb 3, 2025, 7:00 AM EST - 7 months ago

Natera Announces National Commercial Coverage for its Fetal RhD NIPT

Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

Jan 25, 2025, 10:05 AM EST - 7 months ago

Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer

Natera to Present New Data at the 2025 ASCO GI Symposium

Jan 21, 2025, 6:05 PM EST - 7 months ago

Natera to Present New Data at the 2025 ASCO GI Symposium

Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year

Jan 17, 2025, 9:00 AM EST - 7 months ago

Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year

Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection

Jan 15, 2025, 7:00 AM EST - 7 months ago

Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection

Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024

Jan 12, 2025, 7:20 PM EST - 8 months ago

Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024

Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 9:00 AM EST - 8 months ago

Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Undercovered Dozen: Natera, Lloyds Banking Group, Eaton, Primoris Services +

Jan 3, 2025, 2:00 PM EST - 8 months ago

Undercovered Dozen: Natera, Lloyds Banking Group, Eaton, Primoris Services +

LYG PRIM

Natera: Poised For A Great Future But I'd Wait For A Pullback

Dec 31, 2024, 5:50 AM EST - 8 months ago

Natera: Poised For A Great Future But I'd Wait For A Pullback

Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%

Dec 20, 2024, 2:27 PM EST - 8 months ago

Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%

Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics

Dec 17, 2024, 8:00 AM EST - 9 months ago

Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics

Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer

Dec 12, 2024, 8:00 AM EST - 9 months ago

Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer

Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment

Dec 9, 2024, 8:00 AM EST - 9 months ago

Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment

JudithJohnson203
JudithJohnson203 Aug. 25 at 6:22 PM
$NTRA Diagnostics leader, continuation if it holds the breakout base
0 · Reply
ZacksResearch
ZacksResearch Aug. 25 at 5:40 PM
$NTRA unveils AI platform — game-changer for precision oncology? 🚀 Natera's proprietary AI foundation integrates massive datasets to enhance drug development and clinical decision-making. Shares up 2.3% post-announcement, with a 4.6% YTD gain compared to industry's 0.9%. Discover the full impact here 👉 https://www.zacks.com/stock/news/2742434/natera-shares-rise-on-the-launch-of-ai-platform-for-precision-oncology?cid=sm-stocktwits-2-2742434-body-9397&ADID=SYND_STOCKTWITS_TWEET_2_2742434_BODY_9397
0 · Reply
ZacksResearch
ZacksResearch Aug. 25 at 4:40 PM
$NTRA popping on AI-fueled cancer care 🚀 Shares are climbing as the company rolls out its own AI platform, powered by massive oncology datasets to push precision oncology forward. See what’s driving the momentum here 👉 https://www.zacks.com/stock/news/2742434/natera-shares-rise-on-the-launch-of-ai-platform-for-precision-oncology?cid=sm-stocktwits-2-2742434-teaser-9396&ADID=SYND_STOCKTWITS_TWEET_2_2742434_TEASER_9396
0 · Reply
CaptainAmrica
CaptainAmrica Aug. 23 at 5:56 PM
$NTRA. Still working....and Holding.
0 · Reply
JasonCO
JasonCO Aug. 22 at 8:18 PM
$NTRA beast is back
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 22 at 10:20 AM
WATCHLIST AUG 22 2025 $NTRA Natera Launches Proprietary AI Foundation Models Built On 250,000+ Tumor Exomes And 1M+ Plasma Timepoints To Advance Oncology Diagnostics And Therapeutics $FFAI Faraday X Announces FX Super One Multi Purpose Vehicle Successfully Completes First Federal Motor Vehicle Safety Standards Development Tests $QTRX Quanterix Accelerator Laboratory Receives New York State Clinical Laboratory Permit; Permit Approval Enables Expanded Research Capabilities And Underscores Commitment To Accuracy, Reliability, And Scientific Excellence $ROST Ross Stores shares are trading higher after the company reported better-than-expected Q2 EPS results and issued Q4 GAAP EPS guidance above estimates. $AMBO Ambow Education Launches HybriU Events To Power Immersive, AI-Driven Interactive Live Experiences With Global Multi-Language Accessibility
0 · Reply
StockElementCorporation
StockElementCorporation Aug. 21 at 2:38 PM
$NTRA - Up +2.6% today
0 · Reply
StockElementCorporation
StockElementCorporation Aug. 20 at 6:59 PM
$NTRA - Bullish call flow
0 · Reply
vwapsmash_
vwapsmash_ Aug. 18 at 4:21 PM
$NTRA Natera's genetic testing gains traction though reimbursement challenges remain.
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 18 at 10:56 AM
$NTRA loaded
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 18 at 10:56 AM
$NTRA This trial supports a paradigm shift in post-surgical care for MIBC: • ctDNA-positive patients benefit from adjuvant atezolizumab—potentially improving DFS and OS. • ctDNA-negative patients can avoid unnecessary treatment and its associated toxicity, based on high survival rates from surveillance alone.
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 18 at 10:55 AM
$NTRA The phase III IMvigor011 trial, led by Genentech in collaboration with Natera, demonstrates that Signatera™ ctDNA-positive patients treated with atezolizumab (Tecentriq®) experienced statistically significant and clinically meaningful improvements in both disease-free survival (DFS) and overall survival (OS) compared to placebo.
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 18 at 10:54 AM
$NTRA https://www.businesswire.com/news/home/20250818904141/en/IMvigor011-Bladder-Cancer-Trial-Achieves-Positive-Results-with-Signatera-Strongly-Predicting-Adjuvant-Immunotherapy-Benefit
0 · Reply
JarvisFlow
JarvisFlow Aug. 15 at 1:00 PM
Stephens & Co. has adjusted their stance on Natera ( $NTRA ), setting the rating to Overweight with a target price of 183.
0 · Reply
OptionRunners
OptionRunners Aug. 11 at 5:37 PM
$NTRA Trader sold (to close) the September 19th $145 calls 2,000 times for $15.37 and bought (to open) the November 21st $160 calls 2,000 times for $14.02. The trader is rolling the calls out and up for a $1.35 credit
0 · Reply
IN0V8
IN0V8 Aug. 11 at 2:34 PM
$NTRA Buy Piper Sandler raises target price to $220 from $210
0 · Reply
JarvisFlow
JarvisFlow Aug. 11 at 12:30 PM
Piper Sandler updates rating for Natera ( $NTRA ) to Overweight, target set at 210 → 220.
0 · Reply
topstockalerts
topstockalerts Aug. 8 at 2:07 PM
$NTRA primed for continuation.. 🍾🍾
0 · Reply
MaverikIT
MaverikIT Aug. 8 at 1:32 PM
@SouthernItUp @Thelonius_Stonk @rxptgh gapper$ $WLDN $NTRA ....
1 · Reply
Cheetah007
Cheetah007 Aug. 8 at 1:28 PM
$NTRA bullish but it was a missed net loss correct? make more revenue and keep losing money.
0 · Reply
kc5dvg
kc5dvg Aug. 7 at 10:37 PM
$NTRA $8 more please...
0 · Reply
JasonCO
JasonCO Aug. 7 at 9:46 PM
$NTRA
0 · Reply